Arcellx Raises $115m To Advance Novel T-Cell Therapies

First CAR-T In Phase I, Second Construct Heading For Clinic

The company’s first candidate is a BCMA-targeting CAR-T, but Arcellx also is developing ARC T-cells controlled by a synthetic protein. Both have a binding domain that may confer better safety and efficacy than competitors.

Coins and seeds in jars
Arcellx's series C round will fund its T-cell therapy pipeline's growth • Source: Shutterstock

Arcellx, Inc. closed a $115m series C venture capital round on 13 April that it will use to complete a Phase I clinical trial for its first chimeric antigen receptor T-cell (CAR-T) therapy and take the candidate into a Phase II trial. The funding also will support the first clinical trials for the company’s proprietary Antigen Receptor Complex (ARC) and Soluble protein antigen receptor X-linked (SparX) technologies, which together are used to generate controllable T-cells.

CEO Rami Elghandour explained in an interview with Scrip that both types of engineered T-cells use a D domain –...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.